Tango Therapeutics (TNGX) EBIAT: 2020-2025
Historic EBIAT for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $15.9 million.
- Tango Therapeutics' EBIAT rose 154.46% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 18.54%. This contributed to the annual value of -$130.3 million for FY2024, which is 28.07% down from last year.
- Per Tango Therapeutics' latest filing, its EBIAT stood at $15.9 million for Q3 2025, which was up 140.88% from -$38.9 million recorded in Q2 2025.
- Tango Therapeutics' EBIAT's 5-year high stood at $15.9 million during Q3 2025, with a 5-year trough of -$39.9 million in Q1 2025.
- In the last 3 years, Tango Therapeutics' EBIAT had a median value of -$29.2 million in 2024 and averaged -$26.8 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 951,806.78% in 2021, then skyrocketed by 154.46% in 2025.
- Tango Therapeutics' EBIAT (Quarterly) stood at -$22.0 million in 2021, then tumbled by 31.82% to -$29.1 million in 2022, then fell by 5.86% to -$30.8 million in 2023, then dropped by 22.45% to -$37.7 million in 2024, then soared by 154.46% to $15.9 million in 2025.
- Its last three reported values are $15.9 million in Q3 2025, -$38.9 million for Q2 2025, and -$39.9 million during Q1 2025.